奥拉迪约哪里能买？

The U.S. Food and Drug Administration (FDA) has approved oral, once-daily Oradejo prophylaxis to prevent the onset of hereditary angioedema (HAE) in adults and children 12 years of age and older. Taking one capsule daily may prevent HAE attacks by reducing plasma kallikrein activity. So, where can I buy Oradejo?

Oradejo has not yet been launched in the country. Patients in need can go abroad to buy it, or they can obtain the drug through domestic professional overseas medical service organizations (such as Medical Companion Travel), which can be sent directly to their homes to ensure authenticity. For specific prices, please consult Medical Companion Travel Service.

Recommended dose of Oradejo: Take one capsule (150 mg) once daily with food. Patients should not increase or decrease the drug dosage without authorization while receiving Oladiyo treatment. Increasing the drug dosage will not make the condition improve quickly, but will lead to adverse reactions. Therefore, patients should strictly follow the doctor's diagnosis and treatment recommendations and should not use medication without authorization. Oradejo should not be used to treat acute attacks of hereditary angioedema (HAE).

In the pivotal Phase 3 APeX-2 trial, Oladiyo significantly reduced seizures at 24 weeks, and this reduction was sustained through 48 weeks. HAE patients who completed 48 weeks of treatment (150 mg) experienced a reduction in HAE attack rates, from an average of 2.9 attacks per month at baseline to 1.0 attacks per month after 48 weeks of treatment. In the long-term open-label APeX-S trial, patients who completed 48 weeks (150 mg) of treatment had an average exacerbation rate of 0.8 attacks per month.

Oradejo is a plasma kallikrein inhibitor that binds to plasma kallikrein and inhibits its proteolytic activity. Plasma kallikrein is a protease that cleaves high molecular weight kininogen (HMWK) to produce cleaved HMWK (cHMWK) and bradykinin, a potent vasodilator that increases vascular permeability, leading to the swelling and pain associated with HAE.

In patients with HAE due to C1 deficiency or dysfunction of the inhibitor (C1-INH), plasma kallikrein activity is not regulated normally, which leads to an uncontrolled increase in plasma kallikrein activity and leads to angioedema attack. Will reduce plasma kallikrein activity to control excessive bradykinin production in patients hospitalized with HAE.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.